Comparison between immunostaining intensity of VIRMA (a), YTHDF3 (b) and m6A (c) between primary tumor samples and matched metastatic samples; immunostaining intensity of VIRMA (d), YTHDF3 (e) and m6A (f) among different tumor subtypes; comparison between immunostaining intensity of VIRMA (g), YTHDF3 (h) and m6A (i) in primary and metastatic Teratoma samples. This evidence concerns the gene VIRMA and neoplasm.